CSDA, as a novel suppressor of intimal hyperplasia.

Research Project

Project/Area Number	25670592
Research Category	Grant-in-Aid for Challenging Exploratory Research
Allocation Type	Multi-year Fund
Research Field	Cardiovascular surgery
Research Institution	Asahikawa Medical College
Principal Investigator	SAITO Yukihiro 旭川医科大学, 医学部, 講師 (80540583)
Project Period (FY)	2013-04-01 – 2015-03-31
Project Status	Completed (Fiscal Year 2014)
Budget Amount *help	¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000) Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000) Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords	内膜肥厚 / 遺伝子治療
Outline of Final Research Achievements	Background: Intimal hyperplasia (IH) is the main cause of clinical complication after vascular surgery or angioplasty. Objective: The goal of the present study is to investigate the therapeutic efficacy of CSDA on IH. Methods and Results: Gene transfer of CSDA suppressed cellar proliferation (MTS assay) and migration (modified Boyden chamber method) of VSMCs, via down-regulation of E2F，NFkB，SRE，CRE，and HIF activity. We established the wire-injury mouse model. Now we plan the CSDA gene therapy on this model. Conclusion: We believed that CSDA is a novel multi-functional therapeutic molecule for IH.